Guggenheim Maintains Buy on Genmab, Raises Price Target to $58

Guggenheim analyst Michael Schmidt has maintained a Buy rating on Genmab (NASDAQ: GMAB) and increased the price target from $54 to $58. This adjustment reflects a positive outlook on the company's performance.